Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial.

Clin Cancer Res · 2023 · PMC10570678 · PMID 37594724

Europe PMC DOI

hedged sentence

0.0500

closest p · 1.0× alpha

0.0500

boldest claim

The sentences

nearly significantP = 0.05actually significant

In the SELECT study, a nearly significant OS prolongation was observed after adjustment (HR = 0.62, 95% CI, 0.40–1.00, P = 0.05).

also in 3,349 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.